Meta-analysis · people
Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
Pooled trial data link retatrutide to lower blood pressure, total and LDL cholesterol and triglycerides, with no significant change in HDL.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2026
- Journal
- High Blood Press Cardiovasc Prev
What they tested
The team set out to test whether retatrutide changes blood pressure and blood fat levels, based on all the randomized trials they could find.
How the study was done
A systematic review and meta-analysis that pooled randomized controlled trials of retatrutide found in PubMed, Cochrane Library, Scopus and ClinicalTrials.gov. Results were combined with a random-effects model, a method that allows for real differences between trials.

Model. Individual results vary.
What they found
Across the trials, retatrutide lowered systolic blood pressure (the top number) by a weighted mean difference of 6.79 mmHg and diastolic blood pressure (the bottom number) by 2.46 mmHg. A weighted mean difference is an averaged gap between treated and comparison groups. Total cholesterol fell by 21.88 mg/dL, LDL-C (the so-called bad cholesterol) by 13.10 mg/dL and triglycerides (a blood fat) by 40.90 mg/dL, all with p < 0.0001. HDL-C (the so-called good cholesterol) showed no significant change, at -0.01 mg/dL (p = 0.98).
What it doesn’t show
The total cholesterol result varied a lot from trial to trial (I2 = 84%), so that number is less steady than the blood pressure results. The analysis looked at blood pressure and blood fat markers, not at heart attacks, strokes or other heart events.
The paper
Simental-Mendía et al. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev. 2026.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1Randomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: less hunger and overeating vs placebo at higher dosesRandomized trial · people · 2025
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.